Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGSWW) Operating Income (2020 - 2025)

GeneDx Holdings has reported Operating Income over the past 6 years, most recently at -$14.2 million for Q4 2025.

  • Quarterly results put Operating Income at -$14.2 million for Q4 2025, down 261.65% from a year ago — trailing twelve months through Dec 2025 was -$13.1 million (up 43.67% YoY), and the annual figure for FY2025 was -$13.1 million, up 43.67%.
  • Operating Income for Q4 2025 was -$14.2 million at GeneDx Holdings, down from -$3.3 million in the prior quarter.
  • Over the last five years, Operating Income for WGSWW hit a ceiling of $9.0 million in Q2 2025 and a floor of -$324.9 million in Q4 2022.
  • Median Operating Income over the past 5 years was -$44.2 million (2021), compared with a mean of -$66.5 million.
  • Peak annual rise in Operating Income hit 184.7% in 2025, while the deepest fall reached 261.65% in 2025.
  • GeneDx Holdings' Operating Income stood at -$115.8 million in 2021, then tumbled by 180.6% to -$324.9 million in 2022, then soared by 92.11% to -$25.6 million in 2023, then skyrocketed by 134.34% to $8.8 million in 2024, then plummeted by 261.65% to -$14.2 million in 2025.
  • The last three reported values for Operating Income were -$14.2 million (Q4 2025), -$3.3 million (Q3 2025), and $9.0 million (Q2 2025) per Business Quant data.